Adjusting for partial verification or workup bias in meta-analyses of diagnostic accuracy studies

American Journal of Epidemiology

Volumn 175, Issue 8, 2012, Pages 847-853

  De Groot, Joris A H ^a   Dendukuri, Nandini ^c   Janssen, Kristel J M ^a   Reitsma, Johannes B ^b   Brophy, James ^c   Joseph, Lawrence ^c   Bossuyt, Patrick M M ^b   Moons, Karel G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Diagnosis; Meta analysis; Verification bias; Workup bias

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY ASSESSMENT; BAYESIAN ANALYSIS; CANCER; EPIDEMIOLOGY; ETHICS; HISTOLOGY; META-ANALYSIS; PRECISION; PUBLIC HEALTH;

ACCURACY; ARTICLE; BREAST CANCER; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; STANDARD; SYSTEMATIC ERROR; SYSTEMATIC REVIEW (TOPIC);

BAYES THEOREM; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; RECEPTOR, ERBB-2; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 84859698681     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr383     Document Type: Article

References (46)

1. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. Cochrane Diagnostic Test Accuracy Working Group. Ann Intern Med. 2008;149(12):889-897.
2. Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120(8):667-676. (Pubitemid 24106180)
3. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865-2884. (Pubitemid 32923212)
4. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982-990. (Pubitemid 41316441)
5. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol. 2006;187(2):271-281. (Pubitemid 44148267)
6. Zhou XH, Brizendine EJ, Pritz MB. Methods for combining rates from several studies. Stat Med. 1999;18(5):557-566. (Pubitemid 29116974)
7. Whiting P, Rutjes AW, Reitsma JB, et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004;140(3):189-202. (Pubitemid 38155650)
8. Rutjes AW, Reitsma JB, Di Nisio M, et al. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174(4):469-476.
9. Sadatsafavi M, Shahidi N, Marra F, et al. A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy. J Clin Epidemiol. 2010;63(3):257-269.
10. Walter SD, Irwig L, Glasziou PP. Meta-analysis of diagnostic tests with imperfect reference standards. J Clin Epidemiol. 1999;52(10):943-951. (Pubitemid 29486560)
11. Chu H, Chen S, Louis TA. Random effects models in a meta-analysis of the accuracy of two diagnostic tests without a gold standard. J Am Stat Assoc. 2009;104(486):512-523.
12. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299(17):926-930. (Pubitemid 9050459)
13. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39(1):207-215.
14. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282(11):1061- 1066. (Pubitemid 29436454)
15. Harel O, Zhou XH. Multiple imputation for correcting verification bias. Stat Med. 2006;25(22):3769-3786.
16. de Groot JA, Janssen KJ, Zwinderman AH, et al. Multiple imputation to correct for partial verification bias revisited. Stat Med. 2008;27(28):5880- 5889.
17. Met R, Bipat S, Legemate DA, et al. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA. 2009;301(4):415-424.
18. Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144(11):832-841. (Pubitemid 46780619)
19. Mijnhout GS, Hoekstra OS, van Tulder MW, et al. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91(8):1530-1542. (Pubitemid 32319265)
20. Wells PS, Lensing AW, Davidson BL, et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. Ann Intern Med. 1995;122(1):47-53.
21. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176(10):1429-1434. (Pubitemid 46762020)
22. Hsi ED, Tubbs RR. Guidelines for HER2 testing in the UK. J Clin Pathol. 2004;57(3):241-242. (Pubitemid 38338832)
23. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22(5):854-863. (Pubitemid 41103597)
24. Hoang MP, Sahin AA, Ordòñez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113(6):852-859. (Pubitemid 33051521)
25. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5(3):199-207.
26. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195(4):422-428. (Pubitemid 33069666)
27. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92(12):2965-2974.
28. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20(14):3095-3105. (Pubitemid 34791099)
29. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199(4):418-423. (Pubitemid 36411217)
30. Ogura H, Akiyama F, Kasumi F, et al. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer. 2003;10(3):234-240.
31. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121(5):631-636. (Pubitemid 38533994)
32. Lottner C, Schwarz S, Diermeier S, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol. 2005;205(5):577-584. (Pubitemid 40514830)
33. Loring P, Cummins R, O'Grady A, et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol. 2005;13(2):194-200. (Pubitemid 40726859)
34. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19(2):354-363. (Pubitemid 32112846)
35. McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117(6):935-943. (Pubitemid 34564351)
36. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94(11):855-857. (Pubitemid 34705058)
37. Mrozkowiak A, Olszewski WP, Piaścik A, et al. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol J Pathol. 2004;55(4):165-171. (Pubitemid 40321625)
38. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972-1977. (Pubitemid 38544278)
39. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2005;123(5):766-770. (Pubitemid 40586495)
40. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598-6607. (Pubitemid 41339000)
41. Tosteson AN, Weinstein MC, Wittenberg J, et al. ROC curve regression analysis: the use of ordinal regression models for diagnostic test assessment. Environ Health Perspect. 1994;102(suppl 8):73-78. (Pubitemid 24373314)
42. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7(4):457-472.
43. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. London, United Kingdom: Chapman & Hall Ltd; 1995.
44. de Groot JA, Janssen KJ, Zwinderman AH, et al. Correcting for partial verification bias: a comparison of methods. Ann Epidemiol. 2011;21(2):139-148.
45. Lu Y, Dendukuri N, Schiller I, et al. A Bayesian approach to simultaneously adjusting for verification and reference standard bias in diagnostic test studies. Stat Med. 2010;29(24):2532-2543.
46. Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol. 1995;141(13):263-272.